Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml
inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under
conditions of daily practice